Parallax Volatility Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Parallax Volatility Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,178	Closed	-$631K	–	3053
2023 Q1	$631K	Buy	26,178 +6,528	+33%	+$81.9K	﹤0.01%	1670
2022 Q4	$208K	Buy	19,650 +3,528	+22%	+$28.5K	﹤0.01%	2129
2022 Q3	$73K	Buy	16,122 +1,322	+9%	+$6.02K	﹤0.01%	2550
2022 Q2	$59K	Buy	+14,800	New	+$70.2K	﹤0.01%	2442
2022 Q1	–	Sell	-30,177	Closed	-$170K	–	3360
2021 Q4	$170K	Buy	+30,177	New	+$192K	﹤0.01%	1678
2021 Q3	–	Sell	-132	Closed	-$1K	–	2308
2021 Q2	$1K	Sell	132 -2,483	-95%	-$20K	﹤0.01%	1523
2021 Q1	$27K	Buy	+2,615	New	+$36.8K	﹤0.01%	1205

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Parallax Volatility Advisers's PRVB Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 26,178 shares — an estimated $631K sold.

Parallax Volatility Advisers first reported a position in PRVB in Q1 2021 and held it in 7 quarters. The position peaked at $631K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Parallax Volatility Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 26,178 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $631K.
Parallax Volatility Advisers first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Parallax Volatility Advisers's Provention Bio, Inc. Common Stock position peaked at $631K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.